CSL launches Haegarda in the U.S.

CSL Ltd. (ASX:CSL) launched Haegarda (subcutaneous C1-INH, CSL830) in the U.S. to prevent hereditary angioedema (HAE) in adolescent and adult patients. The wholesale acquisition cost (WAC) of 3000 IU is $2,820 and $1,880 for 2000 IU. The drug's label recommends 60 IU/kg twice weekly...